Novartis

817.00
-8.30
(-1.01%)
Market Cap
2,017.21 Cr
EPS
34.50
PE Ratio
23.62
Dividend Yield
3.03 %
Industry
Healthcare
52 Week High
1,248.00
52 Week Low
744.95
PB Ratio
2.79
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,787.40
#1 4,28,857.13
36.71
#1 49,887.20
12.06
#1 9,648
13.77
59.27
6,012.50
1,59,612.98
79.83
8,184.00
0.89
1,600
#1 64.53
57.99
1,525.90
1,23,233.96
25.11
26,520.70
14.17
4,155
47.38
57.43
3,238.90
1,09,619.09
60.42
10,785.70
11.59
1,656
13.54
52.37
2,557.50
1,05,516.96
52.60
10,615.60
19.57
1,942
-16.38
59.98
1,174.80
98,031.82
#1 18.66
28,905.40
12.36
5,578
1.69
54.12
2,019.60
92,203.01
33.50
20,141.50
#1 19.94
1,936
38.82
50.28
859.65
86,500.90
19.53
19,831.50
13.82
3,831
29.92
46.44
1,220.10
70,863.61
20.72
29,559.20
17.55
3,169
-10.04
58.85
29,705.00
63,121.05
47.82
6,097.20
10.80
1,201
16.01
45.94
Growth Rate
Revenue Growth
-9.16 %
Net Income Growth
-17.60 %
Cash Flow Change
153.13 %
ROE
-14.18 %
ROCE
13.85 %
EBITDA Margin (Avg.)
13.44 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
981
771
727
736
569
474
414
433
437
397
395
Expenses
877
656
631
570
478
426
355
373
314
270
275
EBITDA
104
115
96
166
91
48
60
60
123
127
121
Operating Profit %
-0 %
5 %
4 %
-1 %
3 %
3 %
7 %
7 %
17 %
19 %
22 %
Depreciation
4
4
4
3
3
13
12
10
6
3
2
Interest
0
0
1
6
2
6
8
5
2
2
1
Profit Before Tax
93
111
92
158
86
29
40
-4
115
123
118
Tax
14
39
35
79
34
19
19
-0
12
38
31
Net Profit
79
73
57
78
52
10
21
-4
103
85
86
EPS in ₹
24.75
62.04
19.10
28.43
20.97
4.08
8.46
-1.51
41.86
34.50
35.00

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,246
1,433
1,150
1,111
982
1,078
1,002
958
983
925
Fixed Assets
9
7
6
5
15
76
64
24
19
7
Current Assets
1,063
1,264
973
952
807
813
723
709
677
699
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
1,238
1,426
1,144
1,106
968
1,001
938
934
964
918
Total Liabilities
1,246
1,433
1,150
1,111
982
1,078
1,002
958
983
925
Current Liabilities
211
205
183
330
185
233
159
216
160
157
Non Current Liabilities
33
35
47
47
38
124
132
50
48
23
Total Equity
1,002
1,194
920
734
759
721
711
692
776
745
Reserve & Surplus
986
1,178
906
721
747
708
699
679
763
733
Share Capital
16
16
14
12
12
12
12
12
12
12

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
622
-613
51
-38
50
-9
-11
90
-139
26
Investing Activities
719
-631
424
69
274
56
95
87
-153
33
Operating Activities
-60
57
-41
161
-194
-23
-69
39
45
113
Financing Activities
-38
-39
-332
-268
-30
-41
-37
-36
-31
-121

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
70.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.32 %
0.19 %
0.19 %
0.19 %
0.19 %
0.19 %
0.19 %
DIIs
0.79 %
0.84 %
0.78 %
0.78 %
0.78 %
0.78 %
0.79 %
0.79 %
0.78 %
0.76 %
0.53 %
0.53 %
0.53 %
0.53 %
0.53 %
0.53 %
0.53 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
23.34 %
23.03 %
23.09 %
22.98 %
22.88 %
22.94 %
23.02 %
23.01 %
23.03 %
23.08 %
23.29 %
23.21 %
22.95 %
23.04 %
23.05 %
23.01 %
23.11 %
Others
5.20 %
5.46 %
5.45 %
5.56 %
5.66 %
5.60 %
5.52 %
5.52 %
5.51 %
5.48 %
5.18 %
5.39 %
5.65 %
5.57 %
5.55 %
5.59 %
5.49 %
No of Share Holders
41,572
43,784
45,141
44,640
44,370
43,996
43,275
42,622
41,947
43,343
43,992
43,128
41,239
39,265
39,596
38,926
39,133

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 10 10 10 10 10 10 47.5 25 0.00
Dividend Yield (%) 0.00 1.63 1.46 1.99 1.81 1.69 1.76 4.62 3.18 0.00

Corporate Action

Announcements

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A4 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011.Apr 03, 2025
Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011.Apr 03, 2025
Filing Of Intimation Under Regulation 30 For The Receipt Of Draft Tax Assessment Order By The CompanyMar 27, 2025
Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Friday May 09 2025.Mar 27, 2025
Closure of Trading WindowMar 27, 2025
Integrated Filing (Financial)Mar 04, 2025
This Is To Inform That The Company Has Received Order From Assistant Commissioner Of CGST And Central Excise And Disclosure Is Given Pursuant To Regulation 30 Read With Clause 20 Of Para A Of ScheduleFeb 20, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2025
Filing Of Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended December 31 2024Jan 28, 2025
Board Meeting Outcome for Filing Of Outcome Of The Meeting Of Board Of Directors Of Novartis India Limited Held On January 28 2024Jan 28, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Board Meeting Intimation for Approval Of Quarterly Financial Results For The Quarter Ended As On December 31 2024. The Board Meeting Shall Be Held On Tuesday January 28 2025.Dec 27, 2024
Closure of Trading WindowDec 27, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 27, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 05, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 04, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 21, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 20, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 15, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 28, 2024
Filing Of The Outcome Of Board Meeting And Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 24, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 24, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 09, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 30, 2024
Board Meeting Intimation for Board Meeting Intimation For The Consideration And Approval Of Unaudited Financial Results For The Quarter Ended September 30, 2024.Sep 27, 2024
Closure of Trading WindowSep 27, 2024
Filing Of Clarification On The Email Received From BSE Dated September 26, 2024, On The Rumor In Relation To Acquisition Of Novartis India Limited From Its Swiss Parent Company By Alkem LabsSep 26, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 26, 2024
Clarification sought from Novartis India LtdSep 26, 2024
Intimation Of Acquiring Of DESFERAL® (Deferoxamine) Globally From Novartis Pharma AG By Mitem Pharma. The Disclosure In This Regard Is Made By Mitem Pharma Through Press Release Over Businesswire On September 25, 2024.Sep 25, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 23, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 12, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 12, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 09, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 02, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 29, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 26, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 20, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 11, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 05, 2024

Technical Indicators

RSI(14)
Neutral
51.88
ATR(14)
Volatile
26.89
STOCH(9,6)
Neutral
73.96
STOCH RSI(14)
Neutral
68.36
MACD(12,26)
Bullish
3.84
ADX(14)
Weak Trend
14.61
UO(9)
Bearish
47.21
ROC(12)
Uptrend And Accelerating
1.91
WillR(14)
Neutral
-42.78